The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
IQPP Standards Public Comment Period Open +
In accordance with the procedures for developing PPTA Voluntary Standards, these documents are hereby issued for public review, from October 24, 2013 – January 2, 2014. These are proposed revisions to the current IQPP Standards. The following draft documents are issued for public review:Read More
Plasma Donors and Rare Diseases Take Center Stage +Read More
Industry, Donors and Patients to Convene in Vienna +
Brussels, Belgium—The Plasma Protein Therapeutics Association (PPTA), together with Pharmig and IG Plasma are sponsoring a workshop as part of International Plasma Awareness Week, October 13-20. This event is a joint initiative of PPTA and its member companies designed to:Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly.
Read the current issue.